

DESIGN AND EVALUATION OF TRANSDERMAL FILMS OF LORNOXICAM**K. KAVITHA AND MORE MANGESH RAJENDRA*****Department of Pharmaceutics, Bharathi College of Pharmacy, Bharathinagara, Tal- Maddur, Dist- Mandya, Karnataka-571 422. India.****ABSTRACT**

The current research work was an attempt to develop and evaluate matrix-type transdermal therapeutic system containing Lornoxicam with different ratios of hydrophilic and hydrophobic polymeric combinations by the solvent evaporation technique. The physicochemical compatibility of the drug and the polymers was studied by infrared spectroscopy. The results suggested no physicochemical incompatibility between the drug and the polymers. Three transdermal patch formulations (F1, F2 and F7) consists of Hydroxypropyl methyl cellulose E5 and Ethyl cellulose in the ratios of 5:0, 0:5 and 1:1, respectively were prepared. All formulations carried 4% w/v of Tween-80 as penetration enhancer for Lornoxicam and 10% w/v of Polyethylene glycol as plasticizer in dichloromethane and methanol (4:1) as solvent system. The prepared transdermal patches were evaluated for *in vitro* release, moisture absorption, moisture loss and mechanical properties. The diffusion studies were performed by using modified Franz diffusion cells. The formulation, F1 (Hydroxypropyl methyl cellulose E5 alone) showed maximum release of 95.76 ± 1.38 % in 8 h, where as F2 (Ethyl cellulose alone) showed maximum release of 58.64 ± 1.14 % in 24 h. The formulation, F3 with combination of polymers (1:1) showed maximum release of 76.76 ± 2.1 % in 24 h, emerging to be ideal formulations for Lornoxicam and the mechanism of release was diffusion mediated. The developed transdermal patches increase the efficacy of Lornoxicam for the therapy of arthritis and other painful muscular conditions.

KEY WORDS

Hydroxypropyl methyl cellulose, Lornoxicam, NSAID, Skin permeation, Solvent evaporation technique, Transdermal patch, etc.

1. INTRODUCTION

Conventional systems of medication which require multi dose therapy have numerous problems and complications. The design of conventional dosage form, whether a tablet, an injection or a patch, to deliver the right amount of medicine at the right target site becomes complicated if each medication were to be delivered in an optimal and preferred manner to the individual patient. The impetus for the development of novel drug delivery systems, apart from therapeutic efficacy is cost. Redesigning the modules and means to transport medicine into the body is less demanding and more lucrative task. To address these problems, controlled release drug delivery system, a novel drug delivery approach evolves, which facilitates the drug release into systemic circulation at a pre-determined rate ^{1, 2}. Controlled drug release can be achieved by transdermal drug delivery systems (TDDS) which can deliver medicines via the skin portal to systemic circulation at a predetermined rate over a prolonged period of time ^{3, 4, 5}. TDDS has gained a lot of interest during the last decade as it offers many advantages over the conventional dosage forms and oral controlled release delivery systems notably avoidance of hepatic first pass effect, less frequency of administration, reduction in gastrointestinal side effects and improves patient compliance ⁶. For transdermal products the goal of dosage design is to maximize the flux through the skin into the systemic circulation and simultaneously minimize the retention and metabolism of the drug in the skin ⁷.

Lornoxicam is a newer NSAID of oxycam class. It is a strong analgesic and anti-inflammatory agent. Its analgesic activity is comparable to that of opioids (more effective than 10 mg morphine when used at doses > or =

8 mg to control pain after oral surgery). Clinical investigations have established it as a potent analgesic with excellent anti-inflammatory properties in a range of painful and/or inflammatory conditions, including Rheumatoid arthritis and postoperative pain ^{8, 9, 10}.

Like all NSAIDs, Lornoxicam acts by inhibiting the metabolites of COX branch of arachidonic acid pathway. It inhibits both isoforms in the same proportion, a perfectly balanced inhibition of COX-1 and COX-2 is achieved. As Prostaglandins play an important role in gastrointestinal mucosal protection by strengthening the mucosal barrier for acid and in inhibiting gastric acid secretion. Thus inhibition of prostaglandin synthesis leads to adverse effects. The gastric side effects range from mild dyspepsia and heartburn to ulceration and hemorrhage ^{11, 12}.

Lornoxicam is absorbed rapidly and almost completely from the gastro-intestinal tract. Peak plasma concentration is attained within 2.5 hrs. Food reduces the absorption of the drug. The absolute bioavailability of Lornoxicam is 90-100%. It has a relatively short plasma half-life (3 to 5 hours). It is eliminated following biotransformation to 5'-hydroxy-Lornoxicam, which does not undergo enterohepatic recirculation ¹³.

Thus in current research work an attempt was made to develop transdermal patches of Lornoxicam in order to supply local medication to the affected tissues (painful joints), avoid its gastrointestinal side effects and to improve patient compliance by supplying sustained release patch.

2. MATERIALS AND METHODS

2.1. Materials

Lornoxicam was received as a gift samples from Micro Labs, Hosur, India. Hydroxypropyl methyl cellulose (HPMC) E5 and ethyl cellulose (EC) were procured from Shreeji chemicals and Rolex chemical industries Mumbai, India, respectively. Tween-80 and Polyethylene glycol (PEG-400) were procured from S.D Fine chemical Ltd. (Mumbai, India). All other laboratory chemicals used in the study were of analytical reagents grade. Double distilled water was used throughout the study.

2.2. Investigation of physicochemical compatibility of drug and polymer

The physicochemical compatibility between Lornoxicam and polymers used in the films was studied by using Fourier transform-infrared (FT-IR- 8300, Shimadzu Co., Kyoto, Japan) spectroscopy. The pelletization was done by the KBr pellet method^{6, 14, 15}. The FT-IR spectra were recorded in the wavelength region between 4000 and 400 cm^{-1} . The spectra obtained for Lornoxicam and physical mixtures

of Lornoxicam with polymers were compared.

2.3. Preparation of transdermal patch

In the present study, drug loaded matrix type transdermal films of Lornoxicam were prepared by solvent evaporation method^{3, 6, 16}. Teflon plates having diameter of 6 cm and Total area of 28 cm^2 were used. The bottom of the plates was wrapped with aluminium foil, 300 mg of the polymer(s) was accurately weighed and dissolved in 7 ml of Dichloromethane: methanol (4:1) and kept aside to form a clear solution. Polyethylene glycol (PEG-400) was used as plasticizer and Tween-80 is used as a permeation enhancer. 8 mg of Lornoxicam was dissolved in the above solution and mixed for 10 min. The resulted uniform solution was cast on the aluminium foil and dried at 40°C in the hot air oven for 24 h. An inverted funnel was placed over the mould to prevent fast evaporation of the solvent. After 24 h the dried films were taken out and stored in a desiccator for further studies. Compositions of different formulations are represented in Table 1.

Table 1
Composition of different formulations containing Lornoxicam

Formulations	F1	F2	F3
Lornoxicam (mg)	8	8	8
HPMC E-5 (mg)	300	-	150
EC (mg)	-	300	150
PEG-400 (ml)	0.6	0.6	0.6
Tween-80 (ml)	0.25	0.25	0.25
Dichloromethane: Methanol (4:1)	7	7	7

2.4. Evaluation of transdermal patches

1. Physical appearance:

All the prepared patches were visually inspected for color, clarity, flexibility and smoothness⁵.

2. Thickness uniformity:

The thickness of the formulated film was measured at 3 different points using a digital caliper and average thickness of three reading

was calculated¹⁷.

3. Weight uniformity:

For each formulation, three randomly selected patches were used. For weight variation test, 3 films from each batch were weighed individually and the average weight was calculated¹⁸.

4. Folding endurance:

The folding endurance was measured

manually for the prepared films^{17, 19, 20}. A strip of film (3 x 3 cm) was cut and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking/cracking gave the value of folding endurance.

5. Percentage moisture absorption:

The films were weighed accurately and placed

in the desiccators containing 100 ml of saturated solution of potassium chloride, which maintains 80-90% RH^{20, 21}. After 3 days, the films were taken out and weighed. The study was performed at room temperature. The percentage moisture absorption was calculated using the formula:

$$\% \text{ moisture absorption} = \frac{\text{Final weight} - \text{Initial weight}}{\text{Initial weight}} \times 100$$

6. Percentage moisture loss:

The films were weighed accurately and kept in a desiccators containing anhydrous calcium

chloride²². After 3 days, the films were taken out and weighed. The moisture loss was calculated using the formula:

$$\% \text{ moisture loss} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

7. Water vapour transmission rate:

Glass vials of 5 ml capacity were washed thoroughly and dried to a constant weight in an oven. About 1 g of fused calcium chloride was taken in the vials and the polymer films of 2.25 cm² were fixed over the brim with the

help of an adhesive tape. Then the vials were weighed and stored in a humidity chamber of 80-90 % RH condition for a period of 24 h^{7, 23}. The vials were removed and weighed at 24 h time intervals to note down the weight gain.

$$\text{Transmission rate} = \frac{\text{Final weight} - \text{Initial weight}}{\text{Time} \times \text{Area}} \times 100$$

8. Tensile strength:

Tensile strength of the film was determined with Universal strength testing machine (Hounsfield, Slinfold, Horsham, U.K.). The sensitivity of the machine was 1 g. It consisted of two load cell grips. The lower one was fixed and upper one was movable.

The test film of size (4 × 1 cm²) was fixed between these cell grips and force was gradually applied till the film broke^{17, 24}. The tensile strength of the film was taken directly from the dial reading in kg. Tensile strength is expressed as follows:

$$\text{Tensile strength} = \frac{\text{Tensile load at break}}{\text{Cross section area}}$$

9. Drug content uniformity of films:

The patches (1 cm²) were cut and added to a beaker containing 100 ml of phosphate buffered saline of pH 7.4^{5, 25}. The medium was

stirred with magnetic bead. The contents were filtered using whatmann filter paper and the filtrate was examined for the drug content against the reference solution

consisting of placebo films (contains no drug) at 376 nm spectrophotometrically. The experiment was repeated to validate the result.

10. In vitro drug release studies:

In vitro skin permeation studies were performed by using a modified Franz diffusion cell with a receptor compartment capacity of 20 ml^{7, 22}. The synthetic cellophane membrane was mounted between the donor and receptor compartment of the diffusion cell. The formulated patches were cut into size of 1cm² and placed over the drug release membrane and the receptor compartment of the diffusion cell was filled with phosphate buffer pH 7.4. The whole assembly was fixed on a magnetic

stirrer, and the solution in the receptor compartment was constantly and continuously stirred using magnetic beads at 50 rpm; the temperature was maintained at 37 ± 0.5°C. The samples of 1 ml were withdrawn at time interval of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 24 h, analyzed for drug content spectrophotometrically at 376 nm against blank. The receptor phase was replenished with an equal volume of phosphate buffer at each time of sample withdrawal. The cumulative amounts of drug permeated per square centimeter of patches were plotted against time.

3. RESULTS

3.1. Physicochemical compatibility of drug and polymer




Fig. 1

FTIR Spectra of, A= pure drug Lornoxicam, B= Physical mixture of drug and HPMC E5, C= Physical mixture of Lornoxicam and EC.

3.2. Evaluation of transdermal patches:

Table 2

Formulation code	Thickness (mm)	Weight (g)	Folding endurance
F1	0.200 ± 0.020	0.860± 0.017	111.0 ± 4.582
F2	0.203 ± 0.011	0.832 ± 0.017	55.33 ± 6.806
F3	0.190 ± 0.026	0.865 ± 0.017	95.66 ± 7.371

* indicates all the values from tables are in the form of (mean ± SD) for n = 3.

Table 3

Formulation code	%Moisture absorption	% Moisture loss	Drug content in mg
F1	6.973 ± 2.324	12.5 ± 2.50	0.279 ± 0.008
F2	1.753 ± 1.518	9.64 ± 1.51	0.249 ± 0.016
F3	6.348 ± 1.374	9.29 ± 2.32	0.271 ± 0.025

Table 4

Formulation code	Water vapour transmission rate	Tensile strength (kg/mm ²)
F1	0.0045 ± 0.0001	3.84 ± 0.125
F2	0.0026 ± 0.0005	2.96 ± 0.110
F3	0.0042 ± 0.0004	3.41 ± 0.079

Table 5

Formulation code	R Square values			
	Zero Order	First Order	Higuchi	Peppas
F1	0.9901	0.7563	0.9009	0.9865
F2	0.9113	0.9877	0.8958	0.9994
F3	0.9325	0.9816	0.8931	0.9979




Figure 2

1) Physical appearance:

The transdermal patches were transparent, smooth, uniform and flexible.

2) Thickness Uniformity:

The thickness of the patches was varied from 0.190 ± 0.026 mm to 0.203 ± 0.011 mm (Table 2). Low standard deviation values ensured uniformity of the patches.

3) Weight Uniformity:

The weights ranged between 0.832 ± 0.017 mg and 0.860 ± 0.017 mg (Table 2), which indicates that different batches patch weights, were relatively similar.

4) Folding endurance:

Folding endurance was found to be >111 which is sufficient (Table 2)

5) The % moisture loss:

The % moisture loss was found to be between 9.29 ± 2.32 to 12.5 ± 2.50 (Table 3). The moisture loss was found to increase with increasing concentration of hydrophilic polymers

6) The % moisture absorption:

% moisture absorption was found to be 1.753 ± 1.518 to 6.973 ± 2.324 (Table 3), and it increases with increasing concentration of hydrophilic polymers.

7) Water vapour transmission rate:

Water vapour transmission rate for prepared transdermal patches was found to be 0.0026 ± 0.0005 to 0.0045 ± 0.0001 (Table 4).

8) Tensile strength:

The Tensile strength of patches is found in order $F1 > F3 > F1$. As the concentration of hydrophilic polymer was increased there is increase in tensile strength. The mean value was found to vary between 2.96 ± 0.110 to 3.84 ± 0.125 kg/mm² (Table 4).

9) Drug content uniformity of films:

Drug content was found to be 0.249 ± 0.016 mg to 0.279 ± 0.08 mg (Table 3).

3.3 In vitro drug release studies:

The result indicated that the release of drug from patches increases with increasing concentration of HPMC E5. The cumulative percentage of drug release in 8 h was found to be the highest (95.76 ± 1.38 %) from formulation

F1 (Table 5, Fig. 2) and minimum (58.64 ± 1.14 %) from formulation F2. The drug release was found to increase as the concentration of hydrophilic polymer increases. Formulation F3 containing HPMC E5:EC (1:1) showed cumulative % drug release of 76.76 ± 2.1 % in 24 h, emerging as a best formulation by fulfilling the requirement of better and sustained release which was not possible with HPMC E5 and EC alone.

4. DISCUSSION

Lornoxicam in combination with HPMC E5, EC and with incorporation of PEG (10%) and Tween-80 (4%) produced smooth, flexible and transparent films. FT-IR spectral studies indicated there was no interaction between Lornoxicam and polymers used. Lornoxicam patches were prepared with combination of these polymers and evaluated. From the results, it was observed that thickness, weight variation, low moisture loss, low moisture absorption, tensile strength were suitable for maximum stability of the prepared formulations. The drug content of TDDS patches ranged from 0.249-0.279 mg.

The drug release rate increased when the concentration of hydrophilic polymer was increased. The cumulative percentage drug release for F1 was found to be 95.76 ± 1.38 % at 8 h and for F2 it was found 58.64 ± 1.14 % at 24 h. The formulation, F3 [HPMC E5: EC (1:1)] is considered as a best formulation, since it shows maximum *in vitro* drug release as 76.76 ± 2.1 % at 24 h. The drug release kinetics studies showed that, except formulation F1 all other formulations follow first order while formulation F1 follows zero order (Table 5).

5. CONCLUSION

In conclusion, controlled release TDDS patches of Lornoxicam can be prepared using the polymer combinations, HPMC E5: EC (1:1)



with PEG-400 and Tween-80 as plasticizer and enhancer, respectively. The release rate of drug through patches increased when the concentration of hydrophilic polymer was increased. The drug release kinetics of all fabricated patches follows first order kinetics

except F1 showing zero order release kinetics (Table 5). Further, *in vivo* studies have to be performed to correlate with *in vitro* release data for the development of suitable controlled release patches for Lornoxicam.

REFERENCES

1. I Sarath Chandiran, T Sivakumar, B Pavankumar, Preparation and evaluation of aceclofenac loaded biodegradable microspheres. *Int J Pharm Biomed Res*, 1(1): 19-23, (2010).
2. Kshirsagar NA, Drug Delivery Systems. *Indian Journal of Pharmacology*, 32:S54-S61, (2000).
3. Gupta JRD, Irschhiaya R, Garud N, Priyanka Tripathi, Prashant Dubey, Patel JR, Formulation and evaluation of matrix type transdermal patches of Glibenclamide. *Int J Pharm Sci Drug Res*, 1: 46-50, (2009).
4. Vyas SP, Khar RK, Controlled drug delivery concepts and advances, 1st Edn, New Delhi: Vallabh Prakashan: 411-47, (2002).
5. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS, et al., Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer. *Int J Green Pharm*, 2: 129-33, (2008).
6. Patel RP, Patel G, Baria A, Formulation and evaluation of transdermal patch of aceclofenac. *Int J Drug Deliv*, 1: 41-51, (2009).
7. Devi KV, Saisivam S, Maria GR, Deepti PU, Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. *Drug Dev Ind Pharm*, 29(5): 495-503, (2003).
8. Sheth SK, Patel SJ, Shukla JB, Formulation and Evaluation of Taste Masked Oral Disintegrating Tablet of Lornoxicam. *International Journal of Pharma and Bio Sciences*, 2: 1-9, (2010).
9. Rajesh S Jadon, Swadesh Nayak, Sabita Amlan, Vikas Deep Vaidya, Prashant Khemariya, Sandip Sumbhate, et al., Taste masking of Lornoxicam by polymer carrier system and formulation of oral disintegrating tablets. *International Journal of Drug Delivery*, 1: 27-31, (2009).
10. Julia A, Balfour AF, Barradell LB, Lornoxicam: A Review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. *Drugs*, 51(4): 639-57, (1996).
11. Welte SR, Rabbeseda X, Lornoxicam, a new potent NSAID with improved tolerability profile. *Drugs of Today*, 36(1): 55-76, (2000).
12. Balfour JA, Fitton A, Barradell LB, Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. *Drugs*, 51(4): 639-57, (1996).
13. Prasad Byrav DS, Medhi B, Prakash A, Patyar S, Wadhwa S, Lornoxicam: a Newer NSAID. *IJPMR*, 20(1): 27-31, 2009.
14. Shivakumar HN, Jamakandi VG, Mulla JS, Vinay BL, Formulation, characterization and evaluation of matrix-type transdermal patches of a model antihypertensive drug. *Asian J Pharm*, 3: 59-64, (2009).
15. Ubaidulla U, Reddy MVS, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on *in vitro* and *in vivo* characteristics. *AAPS PharmSciTech*, 8(1): E13-20, (2007).



16. Rao YM, Gannu R, Vishnu YV and Kishan V, Development of nitrendipine transdermal patches for in vitro and ex vivo characterization. *Curr Drug Deliv*, 4: 69-76, (2007).
17. Murthy TEGK, Kishore VS, Effect of casting solvent on permeability of antihypertensive drugs through ethyl cellulose films. *J Sci Ind Res*, 67: 147-50, (2008).
18. Patel HJ, Patel JS, Desai BG, Patel KD, Design and evaluation of amlodipine besilate transdermal patches containing film former. *Int J Pharma Res Dev*, 7: 1-12, (2009).
19. Murthy TEGK and Kishore VS, Effect of casting solvent and polymer on permeability of propranolol hydrochloride through membrane controlled transdermal drug delivery system. *Indian J Pharm Sci*, 69(5): 646-50, (2007).
20. Subramanian K, Sathyapriya LS, Jayaprakash S, Prabhu RS, Abirami A, Madhumitha B et al. An Approach to the formulation and evaluation of transdermal DDS of isoxsuprine HCl. *Int J Pharm Sci Tech*, 1(1): 22-8, (2008).
21. Sankar V, Johnson DB, Sivanand V, Ravichandran V, Raghuraman, S, Velrajan G et al., Design and evaluation of nifedipine transdermal patches. *Indian J Pharm Sci*, 65(5): 510-515, (2003).
22. Shinde AJ, Garala KC, More HN, Development and characterization of transdermal therapeutics system of tramadol hydrochloride. *Asian J Pharm*, 2: 265-69, (2008).
23. Pandit V, Khanum A, Bhaskaran S, Banu V, Formulation and evaluation of transdermal films for the treatment of overactive bladder. *Int J Pharm Tech Res*, 1(3): 799-804, (2009).
24. Kulkarni RV, Mutalik S, Hiremath D, Effect of plasticizers on the permeability and mechanical properties of eudragit films for transdermal application. *Ind J Pharm Sci*, 64(1): 28-31, (2002).
25. Rao V, Mamatha T, Mukkanti K and Ramesh. Transdermal drug delivery system for atomoxetine hydrochloride- in vitro and ex vivo evaluation. *Current Trends in Biotechnology and Pharmacy*, 3(2): 188-96, (2009).
26. Satturwar PM, Fulzele SV, Dorle AK, Evaluation of polymerized rosin for the formulation and development of transdermal drug delivery system: A Technical Note. *AAPS PharmSciTech*, 6(4): E649-54, (2005).